NCT04846842 is a Phase 2 clinical trial of Gimatecan in Epithelial Ovarian Cancer, sponsored by Lee's Pharmaceutical Limited.

Who is sponsoring NCT04846842?

NCT04846842 is sponsored by Lee's Pharmaceutical Limited.

What drugs are being tested in NCT04846842?

Interventions in NCT04846842: Gimatecan.

What condition does NCT04846842 study?

NCT04846842 studies Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.

Is NCT04846842 still recruiting?

NCT04846842 is currently status unknown. Last updated 19 April 2021.

Last reviewed 2021-04-19 · How we verify

NCT04846842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Status unknown Phase 2 Last updated 19 April 2021

What this trial tests

Phase 2 trial testing Gimatecan in Epithelial Ovarian Cancer in 46 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
1 July 2022

1 July 2023

Quick facts

Lead sponsor	Lee's Pharmaceutical Limited
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	1 July 2021
Primary completion	1 July 2022
Estimated completion	1 July 2023

Drugs / interventions tested

Gimatecan — full drug profile →

Conditions studied

Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Peritoneal Cancer — all drugs for Peritoneal Cancer →

Sponsor

Lee's Pharmaceutical Limited — full company profile →

Who can join

18 and older, female only, with Epithelial Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer. The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L, Sadilkova L, Viricel W, Dumontet C. · · 2023 · cited 152× · PMID 36650546 · DOI 10.1186/s13045-022-01397-y

Verify or expand the search:

Other trials of Gimatecan

Trials testing the same drug.

NCT04571489 — A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer · Phase 2 · unknown
NCT04501029 — A Study of Gimatecan (ST1481) in Small Cell Lung Cancer · Phase 2 · unknown

Other recruiting trials for Epithelial Ovarian Cancer

Currently open trials in the same condition.

NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other Lee's Pharmaceutical Limited trials

Trials by the same sponsor.

NCT06953453 — A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors · Phase 1 · recruiting
NCT07099144 — Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension · recruiting
NCT06459687 — Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer · Phase 3 · recruiting
NCT06374485 — Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment · Phase 1 · recruiting
NCT05806918 — Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient M · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04846842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lee's Pharmaceutical Limited
Last refreshed: 19 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04846842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing